Validation experiment designed to validate causal mechanisms targeting APP, PSEN1 in transgenic mice expressing chimeric mouse-human APP and mutant human presenilin-1. Primary outcome: amyloid load reduction and cognitive improvement
This experiment tested the therapeutic efficacy of engineered TCRAβ-Tregs in a transgenic mouse model of Alzheimer's disease. Mice expressing chimeric mouse-human amyloid precursor protein and mutant human presenilin-1 received adoptive transfer of the engineered TCRAβ-Tregs. The study measured multiple outcomes including behavioral performance, immune responses, and immunohistochemical markers. Key findings included sustained immune suppression, reduced microglial activation, decreased amyloid loads, and improved cognitive functions. 18F-fluorodeoxyglucose labeling was used to track the TCRAβ-Tregs, demonstrating their ability to home to the brain and provide antigen-specific targeting. The results showed that TCRAβ-Tregs could reduce amyloid burden, restore brain homeostasis, and improve learning and memory compared to controls.
No debates yet
No results recorded yet. Use POST /api/experiments/{id}/results to record a result.